106 related articles for article (PubMed ID: 16552438)
1. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Feliu J; Salud A; Escudero P; Lopez-Gómez L; Bolaños M; Galán A; Vicent JM; Yubero A; Losa F; De Castro J; de Mon MA; Casado E; González-Barón M
Br J Cancer; 2006 Apr; 94(7):969-75. PubMed ID: 16552438
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Park YH; Kim BS; Ryoo BY; Yang SH
Br J Cancer; 2006 Apr; 94(7):959-63. PubMed ID: 16552439
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Feliu J; Safont MJ; Salud A; Losa F; García-Girón C; Bosch C; Escudero P; López R; Madroñal C; Bolaños M; Gil M; Llombart A; Castro-Carpeño J; González-Barón M
Br J Cancer; 2010 May; 102(10):1468-73. PubMed ID: 20424611
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D; Eiermann W; Robert N; Pienkowski T; Martin M; Press M; Mackey J; Glaspy J; Chan A; Pawlicki M; Pinter T; Valero V; Liu MC; Sauter G; von Minckwitz G; Visco F; Bee V; Buyse M; Bendahmane B; Tabah-Fisch I; Lindsay MA; Riva A; Crown J;
N Engl J Med; 2011 Oct; 365(14):1273-83. PubMed ID: 21991949
[TBL] [Abstract][Full Text] [Related]
5. Update on the management of elderly patients with colorectal cancer.
Soler-González G; Sastre-Valera J; Viana-Alonso A; Aparicio-Urtasun J; García-Escobar I; Gómez-España MA; Guillén-Ponce C; Molina-Garrido MJ; Gironés-Sarrió R
Clin Transl Oncol; 2024 Jan; 26(1):69-84. PubMed ID: 37498507
[TBL] [Abstract][Full Text] [Related]
6. Guidance for Treating the Older Adults with Colorectal Cancer.
Ioffe D; Dotan E
Curr Treat Options Oncol; 2023 Jun; 24(6):644-666. PubMed ID: 37052812
[TBL] [Abstract][Full Text] [Related]
7. Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review.
André L; Antherieu G; Boinet A; Bret J; Gilbert T; Boulahssass R; Falandry C
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626074
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia.
Li Q; Jin G; Jiang C; Zhang Z; Hou J; Zhao J; Chen F; Li Z
Arch Med Sci; 2021; 17(5):1440-1446. PubMed ID: 34522277
[No Abstract] [Full Text] [Related]
9. Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies.
Correa E; Lindsay T; Dotan E
Drugs Aging; 2021 Aug; 38(8):639-654. PubMed ID: 34143421
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms.
Szikriszt B; Póti Á; Németh E; Kanu N; Swanton C; Szüts D
Mutagenesis; 2021 Apr; 36(1):75-86. PubMed ID: 33502495
[TBL] [Abstract][Full Text] [Related]
11. Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis.
Yu C; Zhang Y
BMC Gastroenterol; 2020 Oct; 20(1):347. PubMed ID: 33081695
[TBL] [Abstract][Full Text] [Related]
12. Treatment response in elderly patients with advanced colorectal cancer at King Abdulaziz Medical City, Princess Norah Oncology Center, Jeddah.
Leslom AN; Alqahtani FJ; Hanash AAS; Alsubaie AA; Alamri MS
J Family Med Prim Care; 2020 Feb; 9(2):898-903. PubMed ID: 32318442
[TBL] [Abstract][Full Text] [Related]
13. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
Kreidieh M; Mukherji D; Temraz S; Shamseddine A
Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
[TBL] [Abstract][Full Text] [Related]
14. Current status of immunotherapy in metastatic colorectal cancer.
Wrobel P; Ahmed S
Int J Colorectal Dis; 2019 Jan; 34(1):13-25. PubMed ID: 30465238
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer.
Vincent MD; Breadner D; Cripps MC; Jonker DJ; Klimo P; Biagi JJ; Lam W; O'Connell A; Whiston F; Stitt L; Welch SA
Curr Oncol; 2017 Aug; 24(4):e261-e268. PubMed ID: 28874896
[TBL] [Abstract][Full Text] [Related]
16. Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example.
Winther SB; Jørgensen TL; Pfeiffer P; Qvortrup C
ESMO Open; 2016; 1(3):e000021. PubMed ID: 27843604
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.
Ashdown ML; Robinson AP; Yatomi-Clarke SL; Ashdown ML; Allison A; Abbott D; Markovic SN; Coventry BJ
F1000Res; 2015; 4():232. PubMed ID: 26834979
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y; Kanda M; Ishibashi K; Hata T; Kobayashi M; Hasegawa J; Fukunaga M; Takagane A; Otsuji T; Miyake Y; Nagase M; Sakamoto J; Matsuoka M; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():786. PubMed ID: 26497654
[TBL] [Abstract][Full Text] [Related]
19. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Vera R; Serra O; Casado E; Jorge M; Escudero P; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Martínez-Marín V; Maurel J
Br J Cancer; 2014 Jul; 111(2):241-8. PubMed ID: 24946000
[TBL] [Abstract][Full Text] [Related]
20. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Aguado C; García-Paredes B; Sotelo MJ; Sastre J; Díaz-Rubio E
World J Gastroenterol; 2014 May; 20(20):6092-101. PubMed ID: 24876731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
